This company did it the right way by getting EU approval first and then seeking investors outside the market. A fraction of share outstanding compared to POH. Now seeking FDA approval. Just heard the CEO talking about it. He said companies overstate the importance of efficacy to regulator (EU & FDA). The regulators are more concerned with long term safety. I know, If only and what ifs ....Pointless now other than to educate for future investments.
Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
Ann: Phosphagenics Arbitration Award Issued, page-144
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(20.0%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $29.34K | 14.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 33474953 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 44170247 | 21 |
View Market Depth
| Last trade - 11.59am 07/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |